Metaplastic breast carcinomas are basal-like tumours

被引:262
作者
Reis-Filho, J. S.
Milanezi, F.
Steele, D.
Savage, K.
Simpson, P. T.
Nesland, J. M.
Pereira, E. M.
Lakhani, S. R.
Schmitt, F. C.
机构
[1] Inst Canc Res, Breakthrough Toby Robins Breast Canc Res Ctr, London SW3 6JB, England
[2] Univ Minho, Sch Hlth Sci, ICVS, Life & Hlth Sci Res Inst, Braga, Portugal
[3] Univ Porto, IPATIMUP, Inst Mol Pathol & Immunol, Oporto, Portugal
[4] Univ Queensland, Mayne Med Sch, Med Res Inst, Brisbane, Qld, Australia
[5] Royal Brisbane & Womens Hosp, Brisbane, Qld, Australia
[6] Univ Oslo, Norwegian Radium Hosp, Montebello, Norway
[7] Lab Salomao & Zoppi, Sao Paulo, Brazil
[8] Univ Porto, Fac Med, Oporto, Portugal
关键词
carcinosarcoma; epidermal growth factor receptor (HER1); immunohistochemistry; myoepithelial; sarcomatoid carcinoma;
D O I
10.1111/j.1365-2559.2006.02467.x
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Aims: Recently, an immunohistochemical panel comprising antibodies against HER2, oestrogen receptor (ER), epidermal growth factor receptor (EGFR) and cytokeratin (CK) 5/6 was reported to identify basal-like breast carcinomas, as defined by cDNA microarrays. Our aim was to analyse a series of metaplastic breast carcinomas (MBCs) using this panel plus two other basal markers (CK14 and p63) and progesterone receptor (PR), to define how frequently MBCs show a basal-like immunophenotype. Methods and results: Sixty-five cases were retrieved from the pathology archives of the authors' institutions and reviewed by three of the authors. Immunohistochemistry with antibodies for HER2, ER, EGFR, CK5/6, CK14 and p63 was performed according to standard methods. All but six cases (91%) showed the typical immunoprofile of basal-like tumours (ER- and HER2-, EGFR+ and/or CK5/6+). When CK14 and p63 were added to the panel, two additional cases could be classified as basal-like. The majority of MBCs lacked PR, except 4/19 (21%) carcinomas with squamous metaplasia. Conclusions: Our results demonstrate that MBCs show a basal-like phenotype, regardless of the type of metaplastic elements. Moreover, as these neoplasms frequently overexpress EGFR (57%), patients with MBC may benefit from treatment with anti-EGFR drugs.
引用
收藏
页码:10 / 21
页数:12
相关论文
共 47 条
  • [41] METAPLASTIC CARCINOMAS OF THE BREAST .5. METAPLASTIC CARCINOMA WITH OSTEOCLASTIC GIANT-CELLS
    WARGOTZ, ES
    NORRIS, HJ
    [J]. HUMAN PATHOLOGY, 1990, 21 (11) : 1142 - 1150
  • [42] WARGOTZ ES, 1990, CANCER, V65, P272, DOI 10.1002/1097-0142(19900115)65:2<272::AID-CNCR2820650215>3.0.CO
  • [43] 2-6
  • [44] WARGOTZ ES, 1989, CANCER, V64, P1490, DOI 10.1002/1097-0142(19891001)64:7<1490::AID-CNCR2820640722>3.0.CO
  • [45] 2-L
  • [46] METAPLASTIC CARCINOMAS OF THE BREAST .1. MATRIX-PRODUCING CARCINOMA
    WARGOTZ, ES
    NORRIS, HJ
    [J]. HUMAN PATHOLOGY, 1989, 20 (07) : 628 - 635
  • [47] METAPLASTIC CARCINOMAS OF THE BREAST .2. SPINDLE CELL-CARCINOMA
    WARGOTZ, ES
    DEOS, PH
    NORRIS, HJ
    [J]. HUMAN PATHOLOGY, 1989, 20 (08) : 732 - 740